🧬 Scientists Find the "Off Switch" That Exhausts CAR T Cells — and Show How to Flip It

CAR T-cell therapy is one of the most powerful tools in modern oncology: take a patient's own immune cells, genetically reprogram them to hunt cancer, and put them back. It works wonders against some blood cancers. But against solid tumors — the majority of cancer cases — CAR T cells burn out too fast. Now, an international team has pinpointed exactly why.

Researchers at Columbia University and University Hospital Tübingen, led by CAR T pioneer Prof. Michel Sadelain and Prof. Judith Feucht, screened roughly 400 transcription factors — proteins that act as master switches for gene activity inside cells. One protein stood out dramatically: NFIL3. It turned out to be a primary driver of T-cell exhaustion, the process that gradually strips engineered immune cells of their cancer-killing power.

Using CRISPR/Cas9 gene editing, the team snipped out the gene responsible for NFIL3. The result? The edited CAR T cells stayed active significantly longer, multiplied more efficiently, and maintained a sustained anti-tumor assault. In mouse models, NFIL3-disabled cells delivered stronger tumor control and extended survival compared to standard CAR T cells.

Key findings:
— NFIL3 was identified as the dominant transcription factor driving CAR T-cell exhaustion out of ~400 candidates screened
— CRISPR deletion of NFIL3 kept CAR T cells functional and proliferating for much longer periods
— NFIL3-knockout CAR T cells showed superior tumor control across multiple animal models, including solid tumors
— The approach targets the biology of exhaustion itself rather than the tumor type, potentially helping across many cancers

"Switching off NFIL3 could be a decisive step toward significantly improving the long-term potency of CAR T cells," said Prof. Feucht. "We expect this to open up new possibilities in the treatment of cancer patients."

Why it matters: CAR T therapy has been a revolution in blood cancers but has largely failed against solid tumors — breast, lung, pancreatic, brain — because the engineered cells simply don't last. This discovery offers a concrete, druggable target to make CAR T durable enough for the cancers that kill the most people. It's not a new therapy — it's a way to make the existing one finally work where it's needed most.

📄 Original paper (Cancer Discovery): https://doi.org/10.1158/2159-8290.CD-25-1524
📖 Readable summary: https://www.sciencedaily.com/releases/2026/06/260602021641.htm

#CARTcell #CancerResearch #CRISPR #Immunotherapy #Oncology

🧬 Cancer Cells' Favorite Escape Trick Backfires — And Scientists Just Discovered How to Exploit It

For decades, immunologists have operated under a simple assumption: cancer cells evade the immune system by shutting down a protein called MHC class I, which acts as a "wanted poster" for killer T cells. Without this signal, CD8+ killer T cells become blind to the tumor, allowing it to grow unchecked. But a groundbreaking study published in Nature Immunology has now flipped that assumption on its head.

Researchers at Baylor College of Medicine and the University of Michigan discovered that when cancer cells silence MHC I to hide from killer T cells, they inadvertently expose themselves to a completely different immune attack. Instead of becoming invisible, the tumor cells become hyper-visible to CD4+ "helper" T cells — immune cells long thought to play only a supporting role. These helper T cells then trigger ferroptosis, a violent form of cell death driven by iron-catalyzed oxidative stress that essentially rusts the cancer cell from the inside out.

The team, led by Dr. Pavan Reddy at the Dan L Duncan Comprehensive Cancer Center, validated this mechanism across mouse models, human tumor samples, and large clinical datasets from patients who had received checkpoint inhibitor therapies. The results held not only for cancer but also for graft-versus-host disease — a dangerous complication of bone marrow transplants — suggesting the finding rewires our fundamental understanding of T cell biology.

— Cancer cells reduce MHC I to hide from CD8+ killer T cells
— This loss makes them unexpectedly vulnerable to CD4+ helper T cells
— CD4+ cells kill via ferroptosis — iron-driven oxidative destruction
— The same mechanism operates in transplant complications
— Clinical patient data confirms relevance to real-world outcomes

"Our work, if further validated, will have implications for T cell-mediated immune responses beyond cancer and transplant immunology," said Reddy. "This may allow for the development of novel strategies that target MHC class I and CD4+ T cells."

Why it matters: Many aggressive tumors become resistant to immunotherapy precisely because they drop MHC I expression. Until now, this was seen as a dead end. The new discovery suggests these "escaped" tumors may actually be the most vulnerable — if we can learn to weaponize CD4+ T cells against them. It opens a new front in cancer immunotherapy, especially for patients who have stopped responding to existing treatments.

📄 Original paper (Nature Immunology): https://doi.org/10.1038/s41590-026-02480-z
📖 Readable summary (ScienceDaily): https://www.sciencedaily.com/releases/2026/06/260603023911.htm

#Immunology #CancerResearch #Immunotherapy #Science #Breakthrough

🧬 "Undruggable" No More: New Pill Nearly Doubles Survival in Advanced Pancreatic Cancer

For decades, pancreatic cancer has been one of medicine's most hopeless diagnoses. More than 90% of cases are driven by mutations in a gene called KRAS — a protein scientists long labeled "undruggable" because its surface is so unnaturally smooth that no drug could latch onto it. That era just ended.

A new oral drug called daraxonrasib takes a brilliantly indirect approach: instead of trying to bind KRAS directly, it grabs onto a helper molecule called cyclophilin A inside the cell. That drug-protein complex then clamps onto active KRAS and physically shuts it down, silencing the "grow forever" signal at its source. The approach is so novel that it targets multiple mutant forms of RAS at once, making resistance much harder for the cancer to develop.

In a Phase 3 trial of 500 patients with metastatic pancreatic cancer who had already been through prior treatment, the results were striking. Patients on daraxonrasib lived a median of 13.2 months compared to just 6.7 months on standard chemotherapy — nearly double. The drug reduced the overall risk of death by 60%. Results were presented by Revolution Medicines and published in the New England Journal of Medicine.

Side effects are real — a prominent skin rash affected 86% of patients, along with mouth sores, diarrhea, and nausea — but patients on daraxonrasib were far less likely to abandon treatment than those on chemo, and reported better quality of life with less pain.

— Median overall survival: 13.2 months (daraxonrasib) vs 6.7 months (chemotherapy)
— 60% reduction in risk of death
— Once-daily pill — no infusions, no hospital visits
— Works against multiple RAS mutations simultaneously, limiting resistance
— Lower treatment discontinuation rate and improved quality of life vs chemo

"For decades, successfully targeting the central mechanism that causes the vast majority of pancreatic cancers was considered impossible. That narrative is rapidly changing." — Dr. Christopher Lieu, Professor of Medical Oncology, University of Colorado

Why it matters: Pancreatic cancer kills 97% of patients with metastatic disease within five years. Chemotherapy has been our only real tool — a blunt instrument with brutal side effects. Daraxonrasib is the first therapy to go after the genetic engine of the disease itself. If approved, it would be the most significant advance in pancreatic cancer treatment in a generation, and the platform — hijacking cyclophilin A to reach "undruggable" targets — could open doors for dozens of other cancers driven by RAS mutations.

📄 NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2605555
📖 ScienceDaily: https://www.sciencedaily.com/releases/2026/06/260604044247.htm
📖 The Conversation: https://theconversation.com/breakthrough-drug-nearly-doubles-survival-with-advanced-pancreatic-cancer-an-oncologist-explains-how-daraxonrasib-overcame-an-undruggable-disease-283647

#PancreaticCancer #KRAS #CancerResearch #MedicalBreakthrough #science

🐸 A Frog Gut Bacterium Eliminated Colorectal Tumors in Mice

A bacterium found in the gut of Japanese tree frogs has shown a striking anti-cancer effect in mice.

Researchers at the Japan Advanced Institute of Science and Technology (JAIST) screened 45 bacterial strains isolated from amphibians and reptiles, including Japanese tree frogs, fire belly newts, and grass lizards. One strain stood out: Ewingella americana, a naturally occurring bacterium from the intestines of the Japanese tree frog.

In a mouse model of colorectal cancer, a single intravenous dose of E. americana led to complete tumor elimination in all treated mice — a 100% complete response rate in that experiment.

The bacterium appears to work in two ways.

First, it accumulates inside tumors, where oxygen levels are low and blood vessels are unusually leaky. Once there, the bacterial population increased by roughly 3,000 times within 24 hours, directly damaging cancer cells.

Second, it seems to wake up the immune system. The treatment attracted T cells, B cells, and neutrophils into the tumor and boosted inflammatory signals such as TNF-α and IFN-γ, helping the body attack the cancer more aggressively.

The safety data in mice were also encouraging. The bacteria disappeared from the bloodstream within 24 hours, did not colonize healthy organs such as the liver, spleen, lungs, kidneys, or heart, and caused only temporary mild inflammation. Over a 60-day observation period, the researchers reported no chronic toxicity.

But the caveat is essential: this is still mouse research.

Many cancer therapies look spectacular in preclinical models and fail later in humans. A living bacterium injected into the bloodstream would face a much higher safety bar in people, and the human immune response could be very different.

Still, the study is an unusually strong proof of concept for bacterial cancer therapy. Instead of simply changing the gut microbiome, the researchers used a living bacterium as a tumor-targeting agent — one that both attacks cancer cells and recruits the immune system.

The big takeaway: one of the next ideas in cancer therapy may come not from a synthetic drug library, but from the gut of a frog.

Original paper, Gut Microbes:
https://www.tandfonline.com/doi/full/10.1080/19490976.2025.2599562

DOI:
https://doi.org/10.1080/19490976.2025.2599562

ScienceDaily summary:
https://www.sciencedaily.com/releases/2026/07/260709160655.htm

JAIST press release:
https://www.jaist.ac.jp/english/whatsnew/press/2025/12/17-1.html

#CancerResearch #Microbiome #Immunotherapy #Biotech